Remimazolam

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Remimazolam
Remimazolam structure.png
Systematic (IUPAC) name
methyl 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate
Clinical data
Legal status ?
Identifiers
CAS number 308242-62-8 YesY
ATC code ?
PubChem CID 9824461
ChemSpider 8043503 N
UNII 7V4A8U16MB YesY
Chemical data
Formula C21H19BrN4O2 
Mol. mass 439.304
 N (what is this?)  (verify)

Remimazolam[1] (CNS-7056) is a drug which is a benzodiazepine derivative, developed as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trial results showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.[2][3]


See also[edit]

References[edit]

  1. ^ EP Patent 1183243
  2. ^ Rogers WK, McDowell TS (December 2010). "Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures". IDrugs : the Investigational Drugs Journal 13 (12): 929–37. PMID 21154153. 
  3. ^ Saari TI, Uusi-Oukari M, Ahonen J, Olkkola KT (March 2011). "Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology". Pharmacological Reviews 63 (1): 243–67. doi:10.1124/pr.110.002717. PMID 21245208.